BioCentury
ARTICLE | Company News

Debiopharm Grou, Nobelex deal

July 14, 2014 7:00 AM UTC

Debiopharm partnered with Nobelex to develop two antibiotic programs targeting Neisseria gonorrhea and enteric species utilizing a novel mechanism of action. Debiopharm will retain rights to all IP developed under the deal. Debiopharm acquired the programs, which are in the discovery stage, from its acquisition of technology for structure-guided discovery of fatty acid biosynthesis 1 (FAB1) inhibitors from Affinium Pharmaceuticals Ltd., which wound down operations earlier this year. Affinium’s former management founded Nobelex in March (see BioCentury, Feb. 17, 2014). ...